421 related articles for article (PubMed ID: 15768350)
41. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
[TBL] [Abstract][Full Text] [Related]
42. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
43. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
44. Prison health care: activist campaign targets hepatitis, HIV care for prisoners, and continuity of care after release.
McTighe L
AIDS Treat News; 2004 Oct; (406):7. PubMed ID: 15614965
[TBL] [Abstract][Full Text] [Related]
45. Epidemiologic trends in infection, mortality, and transplants related to hepatitis C in Wisconsin.
Gasiorowicz M; Hurie M; Russell A; Hoxie N; Vergeront J
WMJ; 2006 Jan; 105(1):34-9. PubMed ID: 16676489
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C in Puerto Rico: a time for public health action.
Pérez CM; Albizu C; Peña M; Torres EA; Reyes JC; Colón H; Ortiz AP; Suárez E
P R Health Sci J; 2007 Dec; 26(4):395-400. PubMed ID: 18246968
[TBL] [Abstract][Full Text] [Related]
47. The prevalence of HCV antibody in South Australian prisoners.
Miller ER; Bi P; Ryan P
J Infect; 2006 Aug; 53(2):125-30. PubMed ID: 16313963
[TBL] [Abstract][Full Text] [Related]
48. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
Hallinan R; Byrne A; Dore GJ
Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
[TBL] [Abstract][Full Text] [Related]
49. Medical management of HIV-hepatitis C virus coinfection in injection drug users.
Khalsa JH; Kresina T; Sherman K; Vocci F
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S1-6. PubMed ID: 16265605
[TBL] [Abstract][Full Text] [Related]
50. Human immunodeficiency virus type 1 and hepatitis C virus co-infection and viral subtypes at an HIV testing center in Brazil.
Pereira GA; Stefani MM; Martelli CM; Turchi MD; Siqueira EM; Carneiro MA; Martins RM
J Med Virol; 2006 Jun; 78(6):719-23. PubMed ID: 16628586
[TBL] [Abstract][Full Text] [Related]
51. Hepatitis C: a public health response in Kansas.
Taylor C; Waters K
Kans Nurse; 2004 Apr; 79(4):8-9. PubMed ID: 16381345
[TBL] [Abstract][Full Text] [Related]
52. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
Strauss SM; Astone JM; Jarlais DD; Hagan H
Drug Alcohol Depend; 2004 Mar; 73(3):227-36. PubMed ID: 15036545
[TBL] [Abstract][Full Text] [Related]
53. Partners and processes in HIV services for inmates and ex-offenders. Facilitating collaboration and service delivery.
Robillard AG; Gallito-Zaparaniuk P; Arriola KJ; Kennedy S; Hammett T; Braithwaite RL
Eval Rev; 2003 Oct; 27(5):535-62. PubMed ID: 14531318
[TBL] [Abstract][Full Text] [Related]
54. Chronic hepatitis C in the state prison system: insights into the problems and possible solutions.
Imperial JC
Expert Rev Gastroenterol Hepatol; 2010 Jun; 4(3):355-64. PubMed ID: 20528122
[TBL] [Abstract][Full Text] [Related]
55. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010.
Ditah I; Ditah F; Devaki P; Ewelukwa O; Ditah C; Njei B; Luma HN; Charlton M
J Hepatol; 2014 Apr; 60(4):691-8. PubMed ID: 24291324
[TBL] [Abstract][Full Text] [Related]
56. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.
Dolan K; Wirtz AL; Moazen B; Ndeffo-Mbah M; Galvani A; Kinner SA; Courtney R; McKee M; Amon JJ; Maher L; Hellard M; Beyrer C; Altice FL
Lancet; 2016 Sep; 388(10049):1089-1102. PubMed ID: 27427453
[TBL] [Abstract][Full Text] [Related]
57. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
58. Elderly prisoners: a growing and forgotten group within correctional systems vulnerable to elder abuse.
Stojkovic S
J Elder Abuse Negl; 2007; 19(3-4):97-117. PubMed ID: 18160383
[TBL] [Abstract][Full Text] [Related]
59. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection.
Hagan H; Strauss SM; Astone JM; Des Jarlais DC
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S297-303. PubMed ID: 15768338
[TBL] [Abstract][Full Text] [Related]
60. HIV Testing, HIV Positivity, and Linkage and Referral Services in Correctional Facilities in the United States, 2009-2013.
Seth P; Figueroa A; Wang G; Reid L; Belcher L
Sex Transm Dis; 2015 Nov; 42(11):643-9. PubMed ID: 26462190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
